AI + EXCLUSIVE DATA

AI tracks executive moves from sources others don't have

Our proprietary AI analyzes exclusive hiring data to find decision-makers actively evaluating solutions like yours.

10-25 executive leads daily • Direct contact info • First 90 days targeting

Start with:

✓7-day trial • $39/mo or $29/mo annual

✓AI + proprietary hiring database

✓Executive contact details included

INDUSTRY FIRST

Nutcracker Therapeutics Named Industry Veteran Samuel Deutsch As Chief Scientific Officer

Jan 08, 2024•over 1 year ago

Position

Chief Scientific Officer

Company

Nutcracker Therapeutics, Inc.

Samuel Deutsch

EmeryvilleBiotechnology Research

Description

Nutcracker Therapeutics, Inc., a biotechnology company dedicated to developing transformative RNA therapies through its proprietary platform, today announced the promotion of Samuel Deutsch, Ph.D., as the company’s chief scientific officer . Dr. Deutsch has been a part of the Nutcracker team since its inception, and previously served as its executive vice president of Research and Early Development, a role he has held for more than two years.

Company Information

Company

Nutcracker Therapeutics, Inc.

Location

5858 HORTON STREET

Emeryville, California, United States

About

Nutcracker Therapeutics is an RNA therapeutics company that has combined the power of advanced engineering with high-precision biosynthesis to deploy a complete RNA therapeutics platform. Armed with this high-tech advantage, we have developed a wholly owned pipeline of RNA therapeutic programs and established partnership initiatives with top clinical investigators at several leading institutions across the globe. With our platform's ability to accelerate the development of life-changing RNA therapeutics, we seek to advance breakthrough RNA therapies at high velocity through all stages of development across a variety of indications. Our technology platform has the potential to significantly reduce costs and cycle times for RNA therapeutic development, with dramatic advantages in capacity scaling and point-of-care delivery over other RNA manufacturing approaches.

Company News

(6 articles)

Tue, 12 Nov 2024 08:00:00 GMT

Nutcracker Therapeutics Introduces CRDMO Precision Biomanufacturing Solutions for mRNA Drug Developers - Business Wire

Tue, 03 Jun 2025 07:00:00 GMT

Nutcracker Therapeutics Unveils NMU-Symphony™ System for On-demand, Individualized Manufacture of RNA-based Personalized Therapeutics - Business Wire

Wed, 22 Aug 2018 13:34:48 GMT

Nutcracker Therapeutics - Crunchbase

Thu, 01 May 2025 07:00:00 GMT

Nutcracker Therapeutics to Showcase NMU-Symphony™ Platform for Personalized Cancer Therapeutics at Leading Industry Conferences - Business Wire

Fri, 11 Jul 2025 07:00:00 GMT

Elegen and Nutcracker Therapeutics to Pilot First Fully Cell-Free Manufacturing Process for RNA-based Personalized Cancer Therapeutics - Business Wire

Tue, 12 Mar 2024 07:00:00 GMT

Nutcracker Therapeutics to Present Data on mRNA Drug Candidate and Immunomodulatory Cytokine at AACR 2024 - Business Wire

FundzWatch™ Score

Medium Activity

Related People

Executive Insights

Based on hiring data

New executive impact window

87% of new executives make significant technology decisions within first 100 days

Budget influence

C-level executives control 73% of technology spending decisions

Transformation catalyst

65% of new senior hires launch digital transformation initiatives

Vendor review timeline

New executives typically review existing vendors within 6 months